biostudies-literatureUnknown63(1)Yu Y<h4>Context</h4>Xiao-Luo-Wan (XLW), a classical prescription in traditional Chinese medicine, has therapeutic effects on uterine fibroids (UFs). Herein, its anti-UF effects were examined using a systematic pharmacological method.<h4>Objective</h4>To explore the active ingredients of XLW <i>via</i> mass spectrometry and its potential effects on UFs by network pharmacology, molecular docking, and experimental validation.<h4>Materials and methods</h4>A mass spectrometer was used to scrutinize the composition of the XLW drug-containing serum. The critical targets and potential mechanisms of XLW against UFs were predicted by network pharmacology and molecular docking. Next, human uterine leiomyoma cells (UMCs) were treated with 20%, 30%, or 40% XLW serum for 24 h, 48 h or 72 h. Cell viability wPharmaceutical biology201-217https://www.ebi.ac.uk/biostudies/studies/S-EPMC11999358biostudies-literatureIntegrated pharmacoanalysis, bioinformatics analysis, and experimental validation to identify the ingredients and mechanisms of Xiao-Luo-Wan in uterine fibroids treatment.PMC11999358Liu HZhang HYang FYu YfalseIntegrated pharmacoanalysis, bioinformatics analysis, and experimental validation to identify the ingredients and mechanisms of Xiao-Luo-Wan in uterine fibroids treatment.<h4>Context</h4>Xiao-Luo-Wan (XLW), a classical prescription in traditional Chinese medicine, has therapeutic effects on uterine fibroids (UFs). Herein, its anti-UF effects were examined using a systematic pharmacological method.<h4>Objective</h4>To explore the active ingredients of XLW <i>via</i> mass spectrometry and its potential effects on UFs by network pharmacology, molecular docking, and experimental validation.<h4>Materials and methods</h4>A mass spectrometer was used to scrutinize the composition of the XLW drug-containing serum. The critical targets and potential mechanisms of XLW against UFs were predicted by network pharmacology and molecular docking. Next, human uterine leiomyoma cells (UMCs) were treated with 20%, 30%, or 40% XLW serum for 24 h, 48 h or 72 h. Cell viability w2025-01-01T00:00:00Z2025 Dec2026-06-01T17:50:22.51Z2025-06-26T03:06:51.257ZS-EPMC119993584021972810.1080/13880209.2025.2485905